Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
Vera Hirsh, John Glaspy, Paul Mainwaring, Christian Manegold, Rodryg Ramlau, Joseph E EidVolume:
8
Language:
english
DOI:
10.1186/1745-6215-8-8
Date:
December, 2007
File:
PDF, 327 KB
english, 2007